TERN Stock Overview
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Terns Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.91 |
| 52 Week High | US$10.67 |
| 52 Week Low | US$1.45 |
| Beta | 0 |
| 1 Month Change | -16.82% |
| 3 Month Change | 16.15% |
| 1 Year Change | 48.68% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -56.99% |
Recent News & Updates
Recent updates
Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Oct 03
Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?
Jun 14Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Mar 16We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate
Nov 24We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely
Aug 24Shareholder Returns
| TERN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -5.8% | -1.4% | 2.8% |
| 1Y | 48.7% | 4.5% | -9.2% |
Return vs Industry: TERN exceeded the US Pharmaceuticals industry which returned 5.4% over the past year.
Return vs Market: TERN exceeded the US Market which returned -9.7% over the past year.
Price Volatility
| TERN volatility | |
|---|---|
| TERN Average Weekly Movement | 16.7% |
| Pharmaceuticals Industry Average Movement | 11.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: TERN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: TERN's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 41 | Senthil Sundaram | https://www.ternspharma.com |
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity.
Terns Pharmaceuticals, Inc. Fundamentals Summary
| TERN fundamental statistics | |
|---|---|
| Market Cap | US$391.67m |
| Earnings (TTM) | -US$58.77m |
| Revenue (TTM) | US$1.00m |
391.7x
P/S Ratio-6.7x
P/E RatioIs TERN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TERN income statement (TTM) | |
|---|---|
| Revenue | US$1.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.00m |
| Other Expenses | US$59.77m |
| Earnings | -US$58.77m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.19 |
| Gross Margin | 100.00% |
| Net Profit Margin | -5,877.10% |
| Debt/Equity Ratio | 0% |
How did TERN perform over the long term?
See historical performance and comparison